文献速递系统性红斑狼疮

新诊断青少年系统性红斑狼疮的免疫调节药物使用

Immunomodulatory Medication Use in Newly Diagnosed Youth With Systemic Lupus Erythematosus.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2021-09-13

该回顾性队列研究利用2000至2013年行政理赔数据,纳入532例10-24岁新诊断系统性红斑狼疮(SLE)青少年,分析首年免疫调节药物处方填充情况。结果显示78%在首年填充了具有减少糖皮质激素用量作用的免疫调节药物处方,其中羟氯喹69%、免疫抑制剂34%;成人起病者较儿童起病者12个月内填充免疫调节药物的可能性更低。

要点

  • 78%的新诊断青少年SLE患者在首年填充了具有减少糖皮质激素用量作用的免疫调节药物处方。
  • 首年羟氯喹与免疫抑制剂处方填充比例分别为69%和34%。
  • 成人起病较儿童起病者12个月内填充免疫调节药物的可能性更低。

核心结论

  • 在新诊断SLE青少年中,羟氯喹使用普遍但并非全覆盖,首年免疫抑制剂处方使用明显偏低。
  • 需进一步研究识别首年免疫调节药物使用不足的影响因素。

研究设计与样本

  • 采用2000至2013年Clinformatics DataMart行政理赔数据的回顾性队列研究。
  • 纳入10-24岁、新诊断SLE(至少3条相隔大于30天的ICD-9 710.0编码)的532例青少年。

主要发现

  • 532例新诊断SLE青少年中,413例(78%)在首年填充了具有减少糖皮质激素用量作用的免疫调节药物处方。
  • 首年填充羟氯喹处方者366例(69%),填充免疫抑制剂处方者182例(34%)。
  • 成人起病较儿童起病者在12个月内填充免疫调节药物的可能性更低。
  • 未发现其他统计学显著关联,但随日历年推进免疫调节药物填充可能性增加。

临床怎么用

  • 对青少年新诊断SLE应关注首年免疫调节药物处方填充情况,尤其免疫抑制剂使用偏低。
  • 成人起病青少年患者12个月内填充免疫调节药物的可能性更低,需关注该群体用药衔接。

局限性

  • 研究基于行政理赔数据,仅反映处方填充而非实际服药。
  • SLE诊断依赖ICD-9编码,可能存在误分类。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine glucocorticoid-sparing immunomodulatory medication use in youth with systemic lupus erythematosus (SLE) during their first year of care. METHODS: We conducted a retrospective cohort study using administrative claims for 2000 to 2013 from Clinformatics DataMart for youth ages 10-24 years with an incident diagnosis of SLE (≥3 International Classification of Diseases, Ninth Revision codes for SLE [710.0], each >30 days apart). We determined the proportion of subjects filling a prescription for immunomodulatory medications within 12 months of the first SLE code (index date). We used multivariable regression to examine associations between demographic/disease factors and time to prescription fill in the first year, and also between prescription fill at any time after the index date. RESULTS: We identified 532 youth with an incident SLE diagnosis, of which 413 (78%) had a glucocorticoid-sparing immunomodulatory prescription fill in the first year. Prescriptions for hydroxychloroquine and immunosuppressants were filled in the first year by 366 youth (69%) and by 182 (34%), respectively. Those with adult-onset (versus childhood-onset) disease were less likely to fill an immunomodulatory medication by 12 months. No other statistically significant associations were found, although there was increasing likelihood of immunomodulatory medication fills with each subsequent calendar year. CONCLUSION: Among youth with newly diagnosed SLE, hydroxychloroquine use is prevalent although not universal, and prescription immunosuppressant use is notably low during the first year of care. Further research is needed to identify factors contributing to suboptimal immunomodulatory medication use during the first year of care.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Davis A, Chang J, Shapiro S, et al. Immunomodulatory Medication Use in Newly Diagnosed Youth With Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2021. PMID: 32702144. doi:10.1002/acr.24392

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。